Mangalam Drugs & Organics Limited

NSE MANGALAM.NS

Mangalam Drugs & Organics Limited Price to Earnings Ratio (P/E) on February 07, 2025: -18.75

Mangalam Drugs & Organics Limited Price to Earnings Ratio (P/E) is -18.75 on February 07, 2025, a -112.96% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Mangalam Drugs & Organics Limited 52-week high Price to Earnings Ratio (P/E) is 157.15 on February 20, 2024, which is 938.33% above the current Price to Earnings Ratio (P/E).
Mangalam Drugs & Organics Limited 52-week low Price to Earnings Ratio (P/E) is -24.26 on August 26, 2024, which is -29.39% below the current Price to Earnings Ratio (P/E).
Mangalam Drugs & Organics Limited average Price to Earnings Ratio (P/E) for the last 52 weeks is 2.03.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NSE: MANGALAM.NS

Mangalam Drugs & Organics Limited

CEO	Mr. Govardhan Murlidhar Dhoot
IPO Date	May 23, 2005
Location	India
Headquarters	Rupam Building
Employees	432
Sector	Healthcare
Industries Pharmaceuticals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Personal Care Petrochemicals

Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

Key trends

Past 5 years